Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, +19

The Lancet

Hematological MalignancyLymphoid NeoplasiaOncologyTranscend Nhl 001Lisocabtagene Maraleucel +3

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

Paul M. Ridker, Jean MacFadyen, Tom Thurén, +113

The Lancet

InflammationAllergyLung InflammationMedicineMetronomic Therapy +9

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

Ranjana H. Advani, Ian W. Flinn, Leslie Popplewell, +18

New England Journal of Medicine

Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis

Nilanjan Ghosh, Reem Karmali, Vanderson Rocha, +24

Journal of Clinical Oncology

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study

Alison R. Sehgal, Daanish Hoda, Peter A. Riedell, +19

The Lancet Oncology

Hematological MalignancyLymphoid NeoplasiaTransplantationMarrow TransplantationLisocabtagene Maraleucel +8

Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.

Jeremy S. Abramson, Leo I. Gordon, Maria Lia Palomba, +14

Journal of Clinical Oncology

Drug SafetyPivotal TrialEngineeringClinical TherapeuticR/r Aggressive Nhl +12

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

Mahasweta Gooptu, Rizwan Romee, Andrew St. Martin, +22

Blood

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

Nathan Fowler, Felipe Samaniego, Wojciech Jurczak, +25

Journal of Clinical Oncology

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, +14

Blood

Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL

André Goy, Radhakrishnan Ramchandren, Nilanjan Ghosh, +10

Blood